Safety Shot reports $17 million increase in equity from SRM Entertainment shares

Safety Shot (NASDAQ:SHOT) reported a significant increase in its equity, approximately $17 million, driven by the substantial appreciation of its 2,347,142 SRM Entertainment shares, which surged from $0.41 to $7.75 per share between March 31 and June 30, 2025. This appreciation contributed to the company's stockholder equity now exceeding $5 million. Concurrently, Safety Shot recently completed its acquisition of Yerbae Brands Corp. and plans to expand into the cognitive enhancement and sleep aid markets, signaling strategic growth initiatives.

Analysis

Safety Shot, Inc. (NASDAQ:SHOT) has reported a significant, non-operating improvement to its balance sheet, with stockholder's equity now exceeding $5 million. This was primarily driven by the mark-to-market appreciation of its investment in SRM Entertainment, whose shares surged from $0.41 to $7.75 in the quarter ending June 30, 2025. This revaluation added approximately $17 million to Safety Shot's equity, as the value of its 2.35 million SRM shares increased to $18.2 million. Concurrently, the company is executing an aggressive growth strategy, evidenced by the recent acquisition of Yerbae Brands Corp., which dilutes existing SHOT shareholders by approximately 18.36% but expands the company's operational footprint. Further signaling its strategic ambitions, Safety Shot is expanding into the cognitive enhancement and sleep aid markets and has increased its 2024 Equity Incentive Plan by 22 million shares, preparing to incentivize talent for future growth while also creating potential for further shareholder dilution.

Key Decisions for Investors

• Investors should distinguish between the company's improved equity position, which is a result of a non-operating gain from its SRM stock holding, and the performance of its core business operations.
• Evaluate the execution risk and potential synergies associated with the recent Yerbae Brands Corp. acquisition and the planned entry into the competitive nootropics and sleep aid markets, as these will be key drivers of future operational value.
• Monitor the potential for shareholder dilution resulting from the 19.9 million shares issued for the Yerbae acquisition and the newly authorized 22 million shares for the equity incentive plan.